RA0254

antibody from Oursmab

Targeting: FLT1 FLT, VEGFR1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0254

Provider

Oursmab

Product name

Icrucumab (Biosimilar Reference Antibody) (FLT1)

Antibody type

Monoclonal

Description

Icrucumab, fully human immunoglobulin G1 (IgG1) monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1). It functions as a specific VEGFR-1 inhibitor with potential antiangiogenic and antitumor activity. By binding with high affinity to VEGFR-1, icrucumab blocks the interaction between the receptor and its primary ligands, vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF). This blockade inhibits the downstream signaling pathways mediated by VEGFR-1, which are involved in promoting angiogenesis (the formation of new blood vessels), vascular permeability, and the recruitment of pro-tumorigenic myeloid cells. As an IgG1 antibody, it may also engage immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) against VEGFR-1-expressing cells.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.